Benedetta Conte, IDIBAPS, Barcelona, Spain, discusses the exploratory analysis evaluating the prognostic effect of the HER2DX assay, the score of which takes into account tumor size, nodal staging, and 4 gene expression signatures tracking immune infiltration, tumor cell proliferation, luminal differentiation, and the expression of the HER2 amplicon. HER2DX has been standardized and validated in HER2+ disease. In-silico analyses were conducted on various public datasets, demonstrating the B-cell immune signature is strongly prognostic in triple-negative breast cancer (TNBC), which could contribute to the development of biomarkers for de-escalating treatment in TNBC. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.